Sana Biotechnology (NASDAQ:SANA) Stock Price Up 6.6%

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price rose 6.6% during mid-day trading on Thursday . The stock traded as high as $5.54 and last traded at $5.52. Approximately 35,264 shares changed hands during trading, a decline of 99% from the average daily volume of 2,571,801 shares. The stock had previously closed at $5.18.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SANA. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Sana Biotechnology in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Sana Biotechnology Trading Up 8.9 %

The company has a market capitalization of $1.25 billion, a P/E ratio of -3.61 and a beta of 1.45. The business’s 50-day simple moving average is $7.12 and its 200 day simple moving average is $7.45.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). As a group, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.15 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. acquired a new stake in Sana Biotechnology during the 4th quarter valued at $54,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Sana Biotechnology by 42.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock worth $66,000 after acquiring an additional 4,815 shares during the last quarter. Simplex Trading LLC increased its stake in shares of Sana Biotechnology by 31.3% in the fourth quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock worth $73,000 after acquiring an additional 4,313 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock worth $93,000 after acquiring an additional 17,753 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of Sana Biotechnology by 40.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 23,361 shares of the company’s stock worth $95,000 after acquiring an additional 6,673 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.